Jaguar Health Issues Warrants for 11.7M Shares, Significantly Diluting Equity to Reduce Liabilities
JAGX sits 19% above its 52-week low of $0.64 on light trading volume (0.3× avg).
Summary
Jaguar Health issued pre-funded common stock purchase warrants for approximately 11.78 million shares to convert existing royalty interests and Series L and M Preferred Stock, resulting in substantial equity dilution.
Key Events · Financing and Capital Events · JAGX
-
Warrant Issuance
Jaguar Health issued pre-funded common stock purchase warrants for a total of 11,776,281 shares to Iliad Research and Trading, L.P. and Streeterville Capital, LLC.
-
Liability Conversion
These warrants were exchanged for a $1,187,914.07 reduction in Iliad's outstanding royalty interest, an $850,000 reduction in Streeterville's outstanding royalty interest, and the cancellation of Series L and M Preferred Stock held by both parties.
-
Dilutive Terms
The pre-funded warrants are immediately exercisable at a nominal price of $0.001 per share, effectively functioning as common stock and representing significant potential dilution.
Analysis · JAGX · Life Sciences
This filing details a highly dilutive financing event where Jaguar Health converted over $2 million in royalty interests and an unspecified amount of Series L and M Preferred Stock into common stock equivalents. The issuance of pre-funded warrants for approximately 11.78 million shares, with a nominal exercise price, represents a significant increase in the potential outstanding share count. Given the current stock price, the implied value of these warrants is substantially higher than the company's current market capitalization, indicating extreme dilution for existing shareholders. While the conversion reduces the company's liabilities, the method of financing suggests a distressed situation, as it comes at a severe cost to equity holders. This transaction follows recent financing activities and underscores the company's ongoing need to manage its balance sheet through dilutive measures.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.3% of the 496 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.64 to $25.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.